ALIM Alimera Sciences Inc.
3,260
$3.20
$0.08
(2.44%)
| Watchers | 3,260 |
| 52-Wk Low | $2.27 |
| 52-Wk High | $4.38 |
| Market Cap | $167.64M |
| Volume | 43,487.00 |
| 52-Wk High | $4.38 |
| 52-Wk Low | $2.27 |
Alimera Sciences Reports Q1 Loss, Misses Revenue EstimatesBenzinga • 4 days ago
Alimera Sciences (NASDAQ: ALIM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.71 per share a year ago. These...
Share to Feed
Alimera Sciences, Inc. (NASDAQ:ALIM - Get Free Report) saw a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 85,800 shares, a drop of...
Over the last three days, A.I.dvisor has detected that ALIM's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...
This is a Bearish indicator signaling ALIM's price could decline from here. Traders may explore shorting the stock or put options...
Over the last three days, A.I.dvisor has detected that ALIM's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...
This indicator may be signaling that ALIM's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
ATLANTA, March 20, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) ( Alimera or the Company ), a global pharmaceutical company whose mission is to be invaluable to patients...
Protocol AL is studying ILUVIEN or faricimab (6.0 mg) injections versus observation for the prevention of visual acuity loss due to radiation retinopathy ATLANTA, March 19, 2024 (GLOBE NEWSWIRE...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Q4 Net Revenues up 88% to $26.3 million vs. Q4 20222023 Net Revenues up 49% to $80.8 million vs. 2022Increases 2024 Revenue Guidance ATLANTA, March 07, 2024 (GLOBE NEWSWIRE...